TMSB15A

Summary

TMSB15A (thymosin beta 15A, HGNC:30744) is a protein-coding gene on chromosome Xq22.1, encoding Thymosin beta-15A (P0CG34). Plays an important role in the organization of the cytoskeleton.

Predicted to enable actin monomer binding activity. Involved in positive regulation of cell migration. Predicted to be located in cytoskeleton. Predicted to be active in cytoplasm.

Source: NCBI Gene 11013 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 13 total
• MANE Select transcript: NM_021992

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30744
Approved symbol	TMSB15A
Name	thymosin beta 15A
Location	Xq22.1
Locus type	gene with protein product
Status	Approved
Aliases	TMSNB
Ensembl gene	ENSG00000158164
Ensembl biotype	protein_coding
OMIM	300939
Entrez	11013

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000289373, ENST00000924149, ENST00000924150, ENST00000924151

RefSeq mRNA: 1 — MANE Select: NM_021992 NM_021992

CCDS: CCDS14498

Canonical transcript exons

ENST00000289373 — 3 exons

Exon	Start	End
ENSE00001038839	102513682	102514124
ENSE00001458544	102516666	102516739
ENSE00001764836	102515064	102515180

Expression profiles

Bgee: expression breadth ubiquitous, 194 present calls, max score 99.49.

FANTOM5 (CAGE): breadth broad, TPM avg 23.5771 / max 7267.7441, expressed in 738 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199975	22.2895	735
199974	1.2875	217

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
embryo	UBERON:0000922	99.49	gold quality
ganglionic eminence	UBERON:0004023	99.48	gold quality
ventricular zone	UBERON:0003053	99.18	gold quality
cortical plate	UBERON:0005343	99.15	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.99	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.48	gold quality
periodontal ligament	UBERON:0008266	89.28	gold quality
right lung	UBERON:0002167	85.88	gold quality
sperm	CL:0000019	84.60	gold quality
male germ cell	CL:0000015	81.68	gold quality
hair follicle	UBERON:0002073	77.89	silver quality
renal glomerulus	UBERON:0000074	77.57	gold quality
endometrium	UBERON:0001295	77.41	gold quality
metanephros	UBERON:0000081	76.78	gold quality
metanephric glomerulus	UBERON:0004736	76.43	gold quality
prostate gland	UBERON:0002367	76.41	gold quality
adrenal tissue	UBERON:0018303	76.30	gold quality
stromal cell of endometrium	CL:0002255	75.80	gold quality
upper lobe of lung	UBERON:0008948	74.10	gold quality
upper lobe of left lung	UBERON:0008952	73.46	gold quality
lower lobe of lung	UBERON:0008949	73.19	gold quality
ectocervix	UBERON:0012249	72.64	gold quality
ovary	UBERON:0000992	72.13	gold quality
left ovary	UBERON:0002119	72.06	gold quality
lung	UBERON:0002048	72.04	gold quality
endocervix	UBERON:0000458	71.36	gold quality
monocyte	CL:0000576	70.47	gold quality
mononuclear cell	CL:0000842	70.25	gold quality
uterus	UBERON:0000995	69.96	gold quality
body of uterus	UBERON:0009853	69.83	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	1341.95
E-MTAB-10018	yes	867.46
E-MTAB-8221	yes	583.31
E-MTAB-7407	yes	451.85
E-HCAD-10	yes	46.56
E-CURD-11	yes	31.04
E-HCAD-5	yes	23.78
E-GEOD-93593	no	6.28
E-ANND-3	no	1.71

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

30 targeting TMSB15A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-891B	99.59	69.81	1083
HSA-MIR-657	99.48	66.02	848
HSA-MIR-6871-3P	99.43	68.85	741
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-6505-3P	99.34	67.39	1071
HSA-MIR-501-3P	99.33	66.12	651
HSA-MIR-502-3P	99.33	66.12	651
HSA-MIR-4477B	99.23	70.49	1733
HSA-MIR-6071	99.16	67.77	1780
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-10524-5P	99.05	66.08	963
HSA-MIR-4699-5P	98.99	67.50	1210
HSA-MIR-629-5P	98.78	68.72	1032
HSA-MIR-8060	98.61	66.93	1187
HSA-MIR-4684-5P	98.29	67.99	1650
HSA-MIR-4769-3P	97.95	68.17	1002
HSA-MIR-6817-5P	97.95	67.86	1026
HSA-MIR-7855-5P	97.39	67.18	925
HSA-MIR-5586-5P	96.29	68.02	685
HSA-MIR-6750-5P	93.94	66.68	797
HSA-MIR-6822-5P	93.94	66.34	812

Literature-anchored findings (GeneRIF, showing 7)

• TMSL8 is well conserved in many mammalian species. Two isoforms, thymosin beta15a and b, exist at different locations, 1.4Mb apart, on human chromosome X, with 98% identity across the coding sequences. (PMID:17567946)
• Human thymosin beta neuroblastoma has a higher affinity for actin in comparison to thymosin beta4 and promotes cell migration. (PMID:17888914)
• Thymosin beta15 (Tbeta15) was translocated into nuclei following kainic acid (KA) treatments in a subset of entorhinal cortex neurons which are the population that undergo delayed apoptosis after KA treatment. (PMID:18452710)
• findings suggest that increased thymosin beta15 expression correlates with the progression and metastasis of non-small cell lung cancer (PMID:18754322)
• Our data show that the TMSB15A and TMSB15B isoforms have distinct expression patterns in different tumor cell lines and tissues. (PMID:19296525)
• Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer. (PMID:23079573)
• Identification of thymosin beta15, the rat homolog of human thymosin beta 15/thymosin beta NB/thymosin-like 8. Thymosin beta15 levels increase in human prostate cancer, correlating positively with Gleason tumor grade. (PMID:8946830)

Cross-species orthologs

0 orthologs

Paralogs (2): TMSB15B (ENSG00000158427), TMSB15C (ENSG00000269226)

Protein

Protein identifiers

Thymosin beta-15A — P0CG34 (reviewed: P0CG34)

Alternative names: NB thymosin beta, Thymosin-like protein 8

All UniProt accessions (1): P0CG34

UniProt curated annotations — full annotation on UniProt →

Function. Plays an important role in the organization of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization.

Subcellular location. Cytoplasm. Cytoskeleton.

Tissue specificity. Neuroblastoma-specific.

Induction. Down-regulated by TGFB1.

Similarity. Belongs to the thymosin beta family.

RefSeq proteins (1): NP_068832* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001152	Beta-thymosin	Family
IPR038386	Beta-thymosin_sf	Homologous_superfamily

Pfam: PF01290

UniProt features (5 total): compositionally biased region 2, initiator methionine 1, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0CG34-F1	72.08	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 116 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, FERRANDO_TAL1_NEIGHBORS, HORIUCHI_WTAP_TARGETS_DN, MODULE_493, CHANDRAN_METASTASIS_DN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, MODULE_66, MODULE_118, MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN, GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN, GOBP_ACTIN_FILAMENT_ORGANIZATION, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN, MODULE_213, SCHLOSSER_SERUM_RESPONSE_DN, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP

GO Biological Process (2): actin filament organization (GO:0007015), regulation of cell migration (GO:0030334)

GO Molecular Function (3): actin monomer binding (GO:0003785), protein sequestering activity (GO:0140311), actin binding (GO:0003779)

GO Cellular Component (3): filamentous actin (GO:0031941), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
actin cytoskeleton organization	1
supramolecular fiber organization	1
cell migration	1
regulation of cell motility	1
actin binding	1
protein binding	1
molecular sequestering activity	1
cytoskeletal protein binding	1
actin filament	1
protein-containing complex	1
intracellular anatomical structure	1
cellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

592 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMSB15A	KLK3	P07288	663
TMSB15A	CD82	P27701	596
TMSB15A	FARSA	Q9Y285	453
TMSB15A	NDUFC2	O95298	418
TMSB15A	C6orf52	Q5T4I8	377
TMSB15A	ZNF740	Q8NDX6	370
TMSB15A	PWWP4	A0A494C071	369
TMSB15A	REEP5	Q00765	349
TMSB15A	HPN	P05981	338
TMSB15A	A0A087WUM3	A0A087WUM3	331
TMSB15A	FAM227A	F5H4B4	317
TMSB15A	FLNA	P21333	303
TMSB15A	NNMT	P40261	300
TMSB15A	TM4SF18	Q96CE8	294
TMSB15A	KLHL4	Q9C0H6	293

IntAct

0 interactions, top by confidence:

BioGRID (3): TMSB15B (Affinity Capture-RNA), TMSB15A (Affinity Capture-MS), TMSB15A (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A097SRV6, A0A0J1BDH3, O41801, P04605, P0C1K3, P0C766, P0CG34, P0CG35, P0DX04, P12692, P15633, P15835, P18758, P20065, P21113, P21117, P21752, P21753, P26351, P26352, P33248, P33735, P33736, P33737, P34338, P34493, P53768, P60743, P75605, Q12026, Q4UKT5, Q54CC7, Q55GR5, Q5MJ07, Q5MJ08, Q5VSR9, Q66H17, Q6I7R5, Q6SJ84, Q6SJ91

Diamond homologs: O14604, P0CG34, P0CG35, P0DX04, P18758, P20065, P21752, P21753, P26351, P26352, P33248, P34032, P62326, P62327, P62328, P62329, P63312, P63313, P63314, Q5R7H8, Q6S9C5, Q6ZWY8, Q7YRC3, Q8T697, Q95274, Q9DET5, Q9DFJ9, Q9I954, Q9I955, Q9I980, Q9W7M8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

13 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	3
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

304 predictions. Top by Δscore:

Variant	Effect	Δscore
X:102515057:GACTT:G	donor_loss	1.0000
X:102515058:ACTTA:A	donor_loss	1.0000
X:102515059:CTTAC:C	donor_loss	1.0000
X:102515060:TTAC:T	donor_loss	1.0000
X:102515061:TAC:T	donor_loss	1.0000
X:102515062:A:AC	donor_gain	1.0000
X:102515062:ACTTT:A	donor_gain	1.0000
X:102515063:C:CA	donor_gain	1.0000
X:102515063:CT:C	donor_gain	1.0000
X:102515063:CTT:C	donor_gain	1.0000
X:102515063:CTTT:C	donor_gain	1.0000
X:102515063:CTTTC:C	donor_gain	1.0000
X:102515066:T:A	donor_gain	1.0000
X:102515177:TAGC:T	acceptor_gain	1.0000
X:102515181:C:CC	acceptor_gain	1.0000
X:102516660:CCTCA:C	donor_loss	1.0000
X:102516661:CTCA:C	donor_loss	1.0000
X:102516662:TCACC:T	donor_loss	1.0000
X:102516663:CACC:C	donor_loss	1.0000
X:102516664:ACCTG:A	donor_loss	1.0000
X:102516665:C:G	donor_loss	1.0000
X:102514122:TAG:T	acceptor_gain	0.9900
X:102514122:TAGC:T	acceptor_loss	0.9900
X:102514123:AGC:A	acceptor_loss	0.9900
X:102514124:GC:G	acceptor_loss	0.9900
X:102514125:C:CC	acceptor_gain	0.9900
X:102515178:AGC:A	acceptor_gain	0.9900
X:102515179:GC:G	acceptor_gain	0.9900
X:102515180:CC:C	acceptor_gain	0.9900
X:102515733:CACGT:C	donor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000605401 (X:102516747 A>C,G,T), RS1001061185 (X:102516457 C>T), RS1001498183 (X:102518720 T>A), RS1001747688 (X:102518379 T>C), RS1003016151 (X:102515475 T>G), RS1003464184 (X:102513411 G>A), RS1003541613 (X:102515871 C>A), RS1004797053 (X:102516893 T>C), RS1006870398 (X:102515348 A>G), RS1008049772 (X:102514684 T>C), RS1009308182 (X:102515906 C>T), RS1010379415 (X:102516449 G>A), RS1010984708 (X:102513481 C>A), RS1016093145 (X:102516897 G>A,C), RS1016620148 (X:102518338 T>G)

Disease associations

OMIM: gene MIM:300939 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, affects cotreatment, increases expression	4
trichostatin A	affects cotreatment, decreases expression	3
Valproic Acid	decreases expression, decreases methylation, increases expression, affects expression	3
entinostat	affects cotreatment, decreases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Estradiol	decreases expression, affects cotreatment	2
Progesterone	decreases expression, affects cotreatment	2
Tunicamycin	decreases expression	2
Aflatoxin B1	decreases methylation, affects expression	2
lasiocarpine	increases expression	1
terbufos	increases methylation	1
beta-lapachone	decreases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	increases expression, affects cotreatment	1
pentanal	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Zoledronic Acid	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Ethanol	decreases expression	1
Arsenicals	increases methylation	1
Calcitriol	decreases expression, affects cotreatment	1
Carbamazepine	affects expression	1
Coumestrol	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Fonofos	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.